Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.

TP53 gene mutation acute lymphoblastic leukemia genome editing prime editing system treatment resistance

Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
28 Mar 2024
Historique:
revised: 08 03 2024
received: 15 08 2023
accepted: 11 03 2024
medline: 29 3 2024
pubmed: 29 3 2024
entrez: 29 3 2024
Statut: aheadofprint

Résumé

In childhood acute lymphoblastic leukemia (ALL), TP53 gene mutation is associated with chemoresistance in a certain population of relapsed cases. To directly verify the association of TP53 gene mutation with chemoresistance of relapsed childhood ALL cases and improve their prognosis, the development of appropriate human leukemia models having TP53 mutation in the intrinsic gene is required. Here, we sought to introduce R248Q hotspot mutation into the intrinsic TP53 gene in an ALL cell line, 697, by applying a prime editing (PE) system, which is a versatile genome editing technology. The PE2 system uses an artificial fusion of nickase Cas9 and reverse-transcriptase to directly place new genetic information into a target site through a reverse transcriptase template in the prime editing guide RNA (pegRNA). Moreover, in the advanced PE3b system, single guide RNA (sgRNA) matching the edited sequence is also introduced to improve editing efficiency. The initially obtained MDM2 inhibitor-resistant PE3b-transfected subline revealed disrupted p53 transactivation activity, reduced p53 target gene expression, and acquired resistance to chemotherapeutic agents and irradiation. Although the majority of the subline acquired the designed R248Q and adjacent silent mutations, the insertion of the palindromic sequence in the scaffold hairpin structure of pegRNA and the overlap of the original genomic DNA sequence were frequently observed. Targeted next-generation sequencing reconfirmed frequent edit errors in both PE2 and PE3b-transfected 697 cells, and it revealed frequent successful edits in HEK293T cells. These observations suggest a requirement for further modification of the PE2 and PE3b systems for accurate editing in leukemic cells.

Identifiants

pubmed: 38549229
doi: 10.1111/cas.16162
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : JSPS
ID : JP19H03615
Organisme : JSPS
ID : JP22H03037

Informations de copyright

© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185‐3193.
Yang F, Brady SW, Tang C, et al. Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nat Can. 2021;2(8):819‐834.
Yu C‐H, Chang W‐T, Jou S‐T, et al. TP53 alterations in relapsed childhood acute lymphoblastic leukemia. Cancer Sci. 2020;111(1):229‐238.
Hientz K, Mohr A, Bhakta‐Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8(5):8921‐8946.
Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258‐265.
Ng JW, Lama D, Lukman S, Lane DP, Verma CS, Sim AY. R248Q mutation – beyond p53‐DNA binding. Proteins. 2015;83(12):2240‐2250.
Li B, Brady SW, Ma X, et al. Therapy‐induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135(1):41‐55.
Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138(4):673‐684.
Shaul O. How introns enhance gene expression. Int J Biochem Cell Biol. 2017;91(Pt B):145‐155.
Surget S, Khoury MP, Bourdon J‐C. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013;7:57‐68.
Oh L, Hainaut P, Blanchet S, Ariffin H. Expression of p53 N‐terminal isoforms in B‐cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles. BMC Cancer. 2020;20(1):110.
Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819‐823.
Nguyen TTT, Tamai M, Harama D, et al. Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome‐positive lymphoid leukemia cell line using the CRISPR/Cas9 system. Int J Hematol. 2022;116:534‐543.
Nguyen TTT, Tanaka Y, Sanada M, et al. CRISPR/Cas9‐mediated induction of relapse‐specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model. Mol Pharmacol. 2023;103:199‐210.
Tamai M, Inukai T, Kojika S, et al. T315I mutation of BCR‐ABL1 into human Philadelphia chromosome‐positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system. Sci Rep. 2018;8(1):9966.
Anzalone AV, Randolph PB, Davis JR, et al. Search‐and‐replace genome editing without double‐strand breaks or donor DNA. Nature. 2019;576(7785):149‐157.
Everette KA, Newby GA, Levine RM, et al. Ex vivo prime editing of patient haematopoietic stem cells rescues sickle‐cell disease phenotypes after engraftment in mice. Nature Biomedical Engineering. 2023;7(5):616‐628.
Li C, Georgakopoulou A, Newby GA, et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood. 2023;141(17):2085‐2099.
Andreeff M, Kojima K, Padmanabhan S, et al. A multi‐center, open‐label, phase I study of single agent RG7112, a first in class p53‐MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid Leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas (CLL/SCLL). Blood. 2010;116(21):657.
Findley HW Jr, Cooper MD, Kim TH, Alvarado C, Ragab AH. Two new acute lymphoblastic leukemia cell lines with early B‐cell phenotypes. Blood. 1982;60(6):1305‐1309.
Watanabe A, Inukai T, Kagami K, et al. Resistance of t(17;19)‐acute lymphoblastic leukemia cell lines to multiagents in induction therapy. Cancer Med. 2019;8(11):5274‐5288.
Inukai T, Zhang X, Kameyama T, et al. A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B‐precursor acute lymphoblastic leukemia cell lines. Am J Hematol. 2010;85(7):535‐537.
Wang B, Xiao Z, Ko HL, Ren E‐C. The p53 response element and transcriptional repression. Cell Cycle. 2010;9(5):870‐879.
Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017;36(28):3943‐3956.
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double‐stranded DNA cleavage. Nature. 2016;533(7603):420‐424.
Li X, Zhou L, Gao BQ, et al. Highly efficient prime editing by introducing same‐sense mutations in pegRNA or stabilizing its structure. Nat Commun. 2022;13(1):1669.
Adikusuma F, Lushington C, Arudkumar J, et al. Optimized nickase‐ and nuclease‐based prime editing in human and mouse cells. Nucleic Acids Res. 2021;49(18):10785‐10795.
Geurts MH, de Poel E, Pleguezuelos‐Manzano C, et al. Evaluating CRISPR‐based prime editing for cancer modeling and CFTR repair in organoids. Life Sci Alliance. 2021;4(10):e202000940.
Abuhamad AY, Mohamad Zamberi NN, Sheen L, et al. Reverting TP53 mutation in breast cancer cells: prime editing workflow and technical considerations. Cells. 2022;11(10):1612.
Chen PJ, Hussmann JA, Yan J, et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 2021;184(22):5635‐5652.e29.
Panigrahi GB, Slean MM, Simard JP, Pearson CE. Human mismatch repair protein hMutLα is required to repair short slipped‐DNAs of trinucleotide repeats. J Biol Chem. 2012;287(50):41844‐41850.
Evensen NA, Madhusoodhan PP, Meyer J, et al. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B‐lymphoblastic leukemia. Haematologica. 2018;103(5):830‐839.

Auteurs

Thao Nguyen (T)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Tomomi Aida (T)

McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Yuka Iijima-Yamashita (Y)

Department of Advanced Diagnosis, Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.

Minori Tamai (M)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Akiko Nagamachi (A)

Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Higashihiroshima, Japan.

Keiko Kagami (K)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Chiaki Komatsu (C)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Shin Kasai (S)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Koshi Akahane (K)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Kumiko Goi (K)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Toshiya Inaba (T)

Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Higashihiroshima, Japan.

Masashi Sanada (M)

Department of Advanced Diagnosis, Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.

Takeshi Inukai (T)

Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.

Classifications MeSH